DSS announces sale of Celios to Impact BioMedical
Sale Announcement: DSS has sold its Celios air purification asset to Impact BioMedical in an all-equity transaction valued at approximately $1.15 million, as part of its strategy to optimize its portfolio.
Strategic Focus: CEO Jason Grady emphasized that this sale allows DSS to concentrate on core business objectives while enabling Impact BioMedical to enhance the potential of Celios' technology.
Get Free Real-Time Notifications for Any Stock
Analyst Views on DSS
About DSS
About the author
MongoDB Shares Surge 31%; Check Out 20 Stocks Making Moves in Premarket Trading
MongoDB's Strong Performance: MongoDB, Inc. shares surged 31% in pre-market trading after reporting better-than-expected second-quarter results and raising its fiscal 2026 adjusted EPS guidance to between $3.64 and $3.73.
Other Gainers: Notable pre-market gainers included NovaBay Pharmaceuticals (up 66.7% due to a special cash dividend), Bollinger Innovations (up 32.1%), and BioXcel Therapeutics (up 19.5% after announcing Phase 3 data).
Pre-Market Losers: Stocks that declined in pre-market trading included Fenbo Holdings (down 16.8%), SCWorx Corp (down 15.2%), and Beneficient (down 14.3%).
Market Overview: The article provides a snapshot of various stocks' performances in pre-market trading, highlighting significant movements both upward and downward.
DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth
Financial Performance: DSS, Inc. reported a 28% year-over-year revenue growth in Q1 2025, driven by increased sales in printed products and rental income, alongside significant debt reduction and improved operating cash flow.
Strategic Focus: The company is committed to streamlining operations and enhancing shareholder value, with plans for continued development and potential mergers and acquisitions as it positions itself for growth in the latter half of 2025.
